Are we finally nearing a treatment for Alzheimer’s?
Science Weekly
00:00
Lacanaman
Lacanaman targets the amyloid protein. Two-thirds of participants didn't have enough amyloid in the brain to qualify for the trial. The really big difference with this was there was a 27% slowing by more than a quarter of the rate of decline over that 18 month period as opposed to the placebo.
Transcript
Play full episode
